Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dong-A Socio Holdings Co., Ltd. (000640.KS)
Seoul, KR
Dong-A Socio Holdings Co., Ltd., established in Seoul, South Korea in 1932, maintains a prominent role in the pharmaceutical industry both within South Korea and globally. Its diverse product range includes well-known items such as Bacchus, Benachio, and Tempo, alongside various infection management solutions and advanced imaging equipment like the FX-V1 and CLS-S7, which are utilized for surgical and diagnostic purposes. Beyond healthcare, the company offers a selection of beverages, including Gayasan Cheonnyeonsu mineral water, POCARI SWEAT, Narangd cider, Oronamin C, and Oran-C bio-PET. Demonstrating a commitment to innovation, Dong-A Socio Holdings is also developing an mRNA-based COVID-19 vaccine, STP2104, which is currently undergoing Phase I clinical trials. The company provides a wide array of services, encompassing business management, contract manufacturing (CMO) for antibodies and recombinant proteins through pre-clinical studies, clinical trials, and commercial production. Other services include maintenance, repair, and operation (MRO), quarantine, military logistics, and packaging and parcel delivery. They also operate MEDIFLIX, a platform dedicated to medical knowledge-sharing. Furthermore, Dong-A Socio Holdings is engaged in the construction of various industrial facilities, such as biotechnology, pharmaceutical, food production, and logistics warehouses, as well as educational, research, commercial, and public infrastructure. This includes comprehensive design, maintenance, and asset development services. Their capabilities also extend to IT systems, providing both development and maintenance solutions.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.44% | -9.79% | -20.44% | -18.77% | -16.16% | -16.13% | +11.92% | -23.36% | -49.31% | +505.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.2% ★ Q1'26: +6.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+52.2% ★ Q1'26: +11.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.7% Q1'26: +12.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.8% Q1'26: +5.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+5.9% Q1'26: +4.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.5% Q1'26: +4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.43× Q1'26: 3.95× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
704.73B
est: 690.60B (+2.0%)
|
726.17B
est: 809.70B (-10.3%)
|
690.26B
est: 80.40B (+758.5%)
|
707.17B
est: 76.60B (+823.2%)
|
769.69B
est: 76.20B (+910.1%)
|
783.32B
est: 783.60B (0.0%)
|
881.94B
est: 835.00B (+5.6%)
|
1.01T
est: 1.02T (-0.9%)
|
1.13T
est: 623.90B (+81.4%)
|
1.33T
est: 1.30T (+2.2%)
|
1.43T
est: 1.43T (+0.1%)
|
1.54T
1.53T – 1.55T
+7.7% YoY
|
1.66T
1.64T – 1.69T
+8.0% YoY
|
| EBITDA |
134.11B
est: 113.82B (+17.8%)
|
234.68B
est: 133.45B (+75.9%)
|
82.30B
est: 13.25B (+521.1%)
|
-125.30B
est: 12.62B (-1,092.5%)
|
101.97B
est: 12.56B (+711.9%)
|
243.54B
est: 129.15B (+88.6%)
|
136.98B
est: 137.62B (-0.5%)
|
88.10B
est: 168.77B (-47.8%)
|
141.37B
est: 102.83B (+37.5%)
|
194.87B
est: 187.33B (+4.0%)
|
193.15B
est: 205.08B (-5.8%)
|
220.84B
219.76B – 222.77B
+7.7% YoY
|
238.51B
234.98B – 242.74B
+8.0% YoY
|
| EBIT |
107.80B
est: 67.21B (+60.4%)
|
207.29B
est: 78.80B (+163.1%)
|
59.17B
est: 7.82B (+656.2%)
|
-149.45B
est: 7.45B (-2,104.9%)
|
56.39B
est: 7.42B (+660.5%)
|
190.25B
est: 76.26B (+149.5%)
|
77.61B
est: 81.26B (-4.5%)
|
17.36B
est: 99.65B (-82.6%)
|
67.19B
est: 60.71B (+10.7%)
|
105.63B
est: 102.91B (+2.6%)
|
97.77B
est: 112.67B (-13.2%)
|
121.32B
120.73B – 122.38B
+7.7% YoY
|
131.03B
129.09B – 133.35B
+8.0% YoY
|
| Net Income |
47.88B
est: 66.49B (-28.0%)
|
149.05B
est: 164.50B (-9.4%)
|
32.54B
est: 20.08B (+62.0%)
|
-163.98B
est: 32.83B (-599.5%)
|
19.76B
est: 35.29B (-44.0%)
|
162.35B
est: 31.41B (+416.8%)
|
60.27B
est: 48.92B (+23.2%)
|
11.15B
est: 45.09B (-75.3%)
|
57.99B
est: 62.42B (-7.1%)
|
58.02B
est: 61.81B (-6.1%)
|
90.94B
est: 115.23B (-21.1%)
|
84.37B
71.87B – 95.54B
-26.8% YoY
|
78.56B
59.37B – 99.20B
-6.9% YoY
|
| SGA |
81.89B
est: 158.18B (-48.2%)
|
88.95B
est: 185.46B (-52.0%)
|
84.01B
est: 18.42B (+356.2%)
|
71.79B
est: 17.55B (+309.2%)
|
92.79B
est: 17.45B (+431.6%)
|
176.95B
est: 179.48B (-1.4%)
|
196.20B
est: 191.26B (+2.6%)
|
232.80B
est: 234.55B (-0.7%)
|
274.57B
est: 142.90B (+92.1%)
|
299.91B
est: 239.79B (+25.1%)
|
—
est: 262.51B (-100.0%)
|
282.68B
281.30B – 285.16B
+7.7% YoY
|
305.30B
300.78B – 310.71B
+8.0% YoY
|
| EPS |
10,560.00
est: 10,327.00 (+2.3%)
|
29,311.00
est: 25,551.40 (+14.7%)
|
5,311.00
est: 3,119.41 (+70.3%)
|
-26,714.00
est: 5,099.02 (-623.9%)
|
3,219.87
est: 5,481.55 (-41.3%)
|
25,946.00
est: 4,879.61 (+431.7%)
|
9,483.50
est: 7,599.03 (+24.8%)
|
1,732.04
est: 7,003.88 (-75.3%)
|
9,006.80
est: 9,695.15 (-7.1%)
|
9,011.65
est: 9,456.12 (-4.7%)
|
13,718.00
est: 17,626.70 (-22.2%)
|
12,906.25
10,994.58 – 14,615.79
-26.8% YoY
|
12,018.00
9,081.41 – 15,174.83
-6.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.20% | 91.7K | 0.09% |
| 2 | Kodex KOSPI 226490.KS | 0.02% | 127.2K | 0.15% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 11.3K | 0.42% |
| 4 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 464.0K | 0.06% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 818.5K | 0.06% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 97.8K | 0.46% |
| 7 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 9.0K | 0.33% |
| 8 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 12.9K | 0.56% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 249.4K | 0.39% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 178.1K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyun-Min Lee | Executive Director & Head of Business Planning Office | — | male |
| Min-Young Kim | Chief Executive Officer & Executive Director | — | male |
| Seung Hyun Ko | Executive Director, Chief Financial Officer & Head of Management Support Office | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000640.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
